A. Scott Jung

1.4k total citations
19 papers, 419 citations indexed

About

A. Scott Jung is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, A. Scott Jung has authored 19 papers receiving a total of 419 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 8 papers in Pathology and Forensic Medicine and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in A. Scott Jung's work include Colorectal Cancer Treatments and Studies (12 papers), Cancer Genomics and Diagnostics (6 papers) and Genetic factors in colorectal cancer (5 papers). A. Scott Jung is often cited by papers focused on Colorectal Cancer Treatments and Studies (12 papers), Cancer Genomics and Diagnostics (6 papers) and Genetic factors in colorectal cancer (5 papers). A. Scott Jung collaborates with scholars based in United States, United Kingdom and Germany. A. Scott Jung's co-authors include Luke Coyle, Gregor Verhoef, Caroline L. Furness, Alicia Zhang, Nicholas Morley, Kylie D. Mason, Janet Franklin, Eric Van Cutsem, Alessandro Rambaldi and Bruce Allen Bach and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Cancer.

In The Last Decade

A. Scott Jung

18 papers receiving 412 citations

Peers

Countries citing papers authored by A. Scott Jung

Since Specialization

Citations

This map shows the geographic impact of A. Scott Jung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Scott Jung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Scott Jung more than expected).

Fields of papers citing papers by A. Scott Jung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Scott Jung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Scott Jung. The network helps show where A. Scott Jung may publish in the future.

Co-authorship network of co-authors of A. Scott Jung

This figure shows the co-authorship network connecting the top 25 collaborators of A. Scott Jung. A scholar is included among the top collaborators of A. Scott Jung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Scott Jung. A. Scott Jung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL). 2025 ·Journal of Clinical Oncology ·Saurabh Dahiya, Matthew L. Ulrickson, Max S. Topp, Marie José Kersten, Jean A. Yared, Patrick M. Reagan, Ran Reshef, Robin Sanderson, Timothy Voorhees, Sairah Ahmed, A. Scott Jung, (unknown), Jinghui Dong, Joshua D. Winters, Rhine R. Shen, (unknown), (unknown), Loretta J. Nastoupil	0
2	Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma 2022 ·Blood ·Paola Ghione, M. Lia Palomba, Anik R. Patel, Sabela Bobillo, Kevin Deighton, Caron A. Jacobson, (unknown), Anthony J. Hatswell, A. Scott Jung, Steve Kanters, Julia Thornton Snider, Sattva S. Neelapu, (unknown), M. Alan Brookhart, Hervé Ghesquières, John Radford, John G. Gribben	35
3	Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma 2020 ·Leukemia & lymphoma ·Luke Coyle, Nicholas Morley, Alessandro Rambaldi, Kylie D. Mason, Gregor Verhoef, Caroline L. Furness, Alicia Zhang, A. Scott Jung, David Cohan, Janet Franklin	61
4	Clinical validation of the next-generation sequencing-based Extended RAS Panel assay using metastatic colorectal cancer patient samples from the phase 3 PRIME study 2018 ·Journal of Cancer Research and Clinical Oncology ·Nitin Udar, Catherine Lofton–Day, Jun Dong, Darcy Vavrek, A. Scott Jung, Kristen Meier, Anita K. Iyer, (unknown), Karen Gutekunst, Bruce Allen Bach, Marc Peeters, Jean‐Yves Douillard	17
5	Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma 2018 ·Blood ·Luke Coyle, Nicholas Morley, Alessandro Rambaldi, Kylie D. Mason, Gregor Verhoef, Caroline L. Furness, Alicia Zhang, A. Scott Jung, Janet Franklin	17
6	Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer 2017 ·Annals of Oncology ·Salvatore Siena, Andrea Sartore‐Bianchi, Rocio García‐Carbonero, Meinolf Karthaus, Denis Smith, Josep Tabernero, Eric Van Cutsem, (unknown), Michael Boedigheimer, Agnes Ang, (unknown), Bruce Allen Bach, A. Scott Jung, Alberto Bardelli	68
7	A Phase 1/1b tolerability study of rilotumumab alone or in combination with cisplatin and capecitabine in Japanese patients with gastric cancer 2017 ·Japanese Journal of Clinical Oncology ·Toshihiko Doi, Kensei Yamaguchi, Yoshito Komatsu, Kei Muro, Tomohiro Nishina, Takako Eguchi Nakajima, Rui Tang, Hui Yang, Yilong Zhang, A. Scott Jung, Agnes Ang, Hirofumi Yasui	2
8	A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer 2016 ·British Journal of Cancer ·Tae Won Kim, Anneli Elme, Zvonko Kusić, Joon Oh Park, Anghel Adrian Udrea, Sun Young Kim, Joong Bae Ahn, Ricardo Villalobos-Valencia, Srinivasan Krishnan, Ante Bilić, Nebojša Manojlović, Jun Dong, Xuesong Guan, Catherine Lofton–Day, A. Scott Jung, Eduard Vrdoljak	44
9	2184 A phase 2 study of mechanisms of acquired resistance to panitumumab (pmab) plus irinotecan (iri) for metastatic colorectal cancer (mCRC) 2015 ·European Journal of Cancer ·Salvatore Siena, Andrea Sartore‐Bianchi, Meinolf Karthaus, Denis Smith, Rocio García‐Carbonero, Eric Van Cutsem, (unknown), Michael Boedigheimer, R. Sidhu, A. Scott Jung, Kelly S. Oliner, Josep Tabernero, (unknown)	1
10	KRAS/NRAS and BRAF Mutations in the 20050181 Study of Panitumumab + FOLFIRI for the 2ND-Line Treatment of Metastatic Colorectal Cancer: Updated Analysis 2014 ·Annals of Oncology ·Marc Peeters, Kelly S. Oliner, Timothy Price, Andrés Cervantes, Alberto F. Sobrero, Michel Ducreux, Yevhen Hotko, Thierry André, Emily Chan, Florian Lordick, Cornelis J.A. Punt, A. H. Strickland, G. Wilson, Tudor–Eliade Ciuleanu, Laslo Roman, Eric Van Cutsem, Hua Yu, A. Scott Jung, R. Sidhu, Scott D. Patterson	2
11	2Nd-Line Therapies After 1St-Line Therapy with Folfiri in Combination with Cetuximab or Bevacizumab in Patients with Kras Wild-Type Metastatic Colorectal Cancer (Mcrc)-Analysis of the Aio Krk 0306 (Fire 3)- Trial 2014 ·Annals of Oncology ·Dominik Paul Modest, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Thomas Decker, Alexander Kiani, Ursula Vehling‐Kaiser, Salah‐Eddin Al‐Batran, Tobias Heintges, Christian Lerchenmüller, Christoph Kahl, G. Seipelt, Frank Kullmann, Martina Stauch, Werner Scheithauer, Swantje Held, Clemens Gießen, A. Scott Jung, Thomas Kirchner, Volker Heinemann	3
12	Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). 2014 ·Journal of Clinical Oncology ·Marc Peeters, Kelly S. Oliner, Timothy Price, Andrés Cervantes, Alberto Sobrero, Michel Ducreux, Yevhen Hotko, Thierry André, Emily Chan, Florian Lordick, Cornelis J.A. Punt, Andrew Strickland, G. Wilson, Tudor–Eliade Ciuleanu, Laslo Roman, Eric Van Cutsem, Ying Tian, A. Scott Jung, Roger Sidhu, Scott D. Patterson	35
13	Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). 2014 ·Journal of Clinical Oncology ·Marc Peeters, Kelly S. Oliner, Timothy Price, Andrés Cervantes, Alberto Sobrero, Michel Ducreux, Yevhen Hotko, Thierry André, Emily Chan, Florian Lordick, Cornelis J.A. Punt, Andrew Strickland, G. Wilson, Tudor–Eliade Ciuleanu, Laslo Roman, Eric Van Cutsem, Hua Yu, A. Scott Jung, Roger Sidhu, Scott D. Patterson	33
14	BRAF-Mutationstestung beim metastasierten malignen Melanom 2012 ·Der Pathologe ·Manfred Dietel, Alexander Enk, Annika Lehmann, Jürgen Bauer, Claus Garbe, Udo Kellner, Thomas Kirchner, A. Scott Jung, Hans Kreipe, Sabine Merkelbach‐Bruse, Reinhard Büttner, Josef Rüschoff, W. Schlake, Peter Schirmacher, (unknown), Rudolf Stadler	6
15	Tensin2 is a novel mediator in thrombopoietin (TPO)-induced cellular proliferation by promoting Akt signaling 2011 ·Cell Cycle ·A. Scott Jung, Alexis Kaushansky, Gavin MacBeath, Kenneth Kaushansky	20
16	Molecular markers of the EGFR pathway in erlotinib-treated patients with advanced pancreatic cancer (APC): Translational analyses of a randomized, cross-over AIO phase III trial. 2011 ·Journal of Clinical Oncology ·Stefan Boeck, A. Scott Jung, Rüdiger P. Laubender, Jens Neumann, (unknown), (unknown), Ursula Vehling‐Kaiser, (unknown), Ludwig Fischer von Weikersthal, Michael Clemens, Thomas Gauler, Angela Märten, Stefan Klein, G. Kojouharoff, (unknown), Michael Geißler, Tim F. Greten, Ulrich Mansmann, Thomas Kirchner, Volker Heinemann	5
17	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (mCRC): Analysis of patients with KRAS-mutated tumors in the randomized German AIO study KRK-0306. 2011 ·Journal of Clinical Oncology ·Sebastian Stintzing, Jens Neumann, A. Scott Jung, Ludwig Fischer von Weikersthal, Thomas Decker, Ursula Vehling‐Kaiser, E. Jaeger, Tobias Heintges, Claude Stoll, Dominik Paul Modest, Thomas Kirchner, Werner Scheithauer, Volker Heinemann	15
18	Autologous Hematopoietic Stem Cell Transplantation as an Intensive Consolidation Therapy for Adult Patients in Remission from Acute Myelogenous Leukemia 2009 ·Biology of Blood and Marrow Transplantation ·A. Scott Jung, Peter Holman, Januario E. Castro, Ewa Carrier, Asad Bashey, Thomas A. Lane, (unknown), Minya Pu, Karen Messer, Sue Corringham, Edward D. Ball	11
19	Relationship between microsatellite instability, response and survival in palliative patients with colorectal cancer undergoing first-line chemotherapy. 2003 ·PubMed ·Wolfgang M. Brueckl, Christian Mœsch, Thomas Brabletz, Corinna Koebnick, Christian U. Riedel, A. Scott Jung, Susanne Merkel, (unknown), Frank Boxberger, Thomas Kirchner, Werner Hohenberger, Eckart G. Hahn, A. Wein	44

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact